Friday, December 7, 2012

What can cloud computing do for big data?

While finance, manufacturing, and even government have embraced the potential Big Data presents, the pharmaceutical industry has taken more of a wait and see approach. Recently, given both the overwhelming amount of available data and the fact that traditional pharma approaches to innovation haven’t quite net the results that have been hoped for, a bet on big data for drug development applications makes sense. It’s clear now that the industry tapping into this opportunity.

At Data-Driven Drug Development (D4), pharmaceutical executives as well as a variety of organizations will discuss what they are seeing and what they are doing to take advantage of the data available. In today's featured session, sessions such as, “Using the Cloud – When is the Right Choice?" you will hear how companies are utilizing data to promote drug development.  For more information on this event, taking place January 28-29, 2013, download the agenda.  If you'd like to join us in Philadelphia, register today and mention code XP1715BLOG to save 15% off the standard rate.

Featured Session: Using the Cloud – When Is it the Right Choice?

Featured Speaker: Mollie Shields-Uehling, President and CEO, SAFE-BIOPHARMA

About the Session: Drug development has become a spider web of global relationships, driven in part by the availability of Internet communication. This interconnectedness requires a secure way to transmit data with trust in the identities of the communicating parties and the ability to allow those presenting themselves to online applications to authenticate their identities. Identity, trust and the ability to apply non-repudiable digital signatures to electronic documents, is at the core of unleashing cloud computing for global drug development.

This session will:
  • • Discusses the role of identity trust in the drug development process
  • • Details an award-winning case study in which cancer researchers for the National Cancer Institute and counterparts at Bristol-Myers Squibb and Sanofi used interoperable digital identities to access, sign and exchange documents involved in the clinical trial start-up process
  • • Explains processes and reports on dramatic ROI time and cost savings

Share this article with your social network, just click below to share now!

No comments :

Post a Comment